rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Onconetix, Inc.

ONCO · Nasdaq

Health CareBiotechnologyNot moving yet

ONCO stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 88.9% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

SEC filings

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$306K
Insider sales, 12 months
$289K
Officials’ trades on record
0
Institutions holding
5 (+0)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$268K$0$284KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months3
Sale orders, 12 months3
Buyers · sellers1 · 1
WhoDidSharesTraded
Hrt Financial Lp10% ownersold49,710at $0.6921 Apr 2026filed 22 Apr 2026
Hrt Financial Lp10% ownersold94,462at $0.7520 Apr 2026filed 21 Apr 2026
Hrt Financial Lp10% ownerbought34,636at $0.7317 Apr 2026filed 21 Apr 2026
Hrt Financial Lp10% ownersold53,867at $0.7316 Apr 2026filed 21 Apr 2026
Hrt Financial Lp10% ownerbought92,554at $0.7615 Apr 2026filed 16 Apr 2026
Hrt Financial Lp10% ownerbought74,350at $0.7714 Apr 2026filed 16 Apr 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders5+0 on the quarter
New · exited3 · 3
Reported value$16K

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
XTX Topco Ltdnew · filed 14 Aug 202613,548$15K+13,548
SBI Securities Co., Ltd.added · filed 23 Jul 2026252$285+132+110.0%
Tower Research Capital LLC (TRC)reduced · filed 11 Aug 2026145$164-1,309−90.0%
HOLLENCREST CAPITAL MANAGEMENTnew · filed 13 Aug 2026100$113+100
MORGAN STANLEYnew · filed 13 Aug 202621$24+21
30 Jun 2025 – 30 Jun 2026
578Jun 25Sep 25Dec 25Mar 26Jun 26

Everyone who traded it

HRT FINANCIAL LP Company insider10% owner · last 21 Apr 20263 · 3
Andrew John Oakley Company insiderDirector · last 15 Aug 20250 · 0
Simon Tarsh Company insiderDirector · last 15 Aug 20250 · 0
Thomas Meier Company insiderDirector · last 15 Aug 20250 · 0
Timothy R. Ramdeen Company insiderDirector · last 15 Aug 20250 · 0
Altos Venture Ag Company insider10% owner · last 14 Jul 20250 · 0
Christian Bruhlmann Company insiderChief Strategy Officer · last 20 Dec 20240 · 0
Ralph Schiess Company insiderInterim CEO, CSO · last 20 Dec 20240 · 0
Ajit Singh Company insiderDirector · last 26 Sep 20240 · 0
James Sapirstein Company insiderDirector · last 26 Sep 20240 · 0
Vuk Jeremic Company insiderDirector · last 31 May 20230 · 0
Erin Henderson Company insiderChief Business Officer · last 9 May 20230 · 1

Same industry

MRNA ModernaLeading+147%
IOVA Iovance BiotherapeuticsLeading+126%
ABCL AbCellera BiologicsLeading+60%
HALO Halozyme TherapeuticsLeading+46%
XERS Xeris Biopharma HoldingsLeading+38%
ENTX Entera BioLeading+37%
HELP Helus PharmaLeading+36%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202577.6%
Return on capital employedFY 2025 · to 31 Dec 2025-113%
Share count trendFY 2025 · to 11 Mar 2026130%
Cash and equivalentsFY 2025 · to 31 Dec 2025$5.2M

Analyst forecasts

No analyst forecasts yet.